Indivior PLC Total Liabilities
Indivior PLC total liabilities. Based on the latest financial reports, Indivior PLC (INDV) has total liabilities worth GBX1.71 Billion GBX (≈ $208.06K USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INDV asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Indivior PLC (2011–2024)
Total liabilities of Indivior PLC from 2011 to 2024. This chart illustrates how Indivior PLC's total liabilities have evolved over time, based on quarterly financial data.
Indivior PLC Competitors by Total Liabilities
The table below lists competitors of Indivior PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PERFORMANCE SHIPP.
F:DS2
|
Germany | €236.42 Million |
|
Lipidor Ab
ST:LIPI
|
Sweden | Skr3.86 Million |
|
Daesung Eltec Co. Ltd
KQ:025440
|
Korea | ₩342.88 Billion |
|
Smithson Investment Trust PLC
LSE:SSON
|
UK | GBX1.63 Million |
|
Eureka Design Public Company Limited
BK:UREKA
|
Thailand | ฿324.34 Million |
|
Assura PLC
LSE:AGR
|
UK | GBX1.64 Billion |
|
YoungWoo DSP Co.Ltd
KQ:143540
|
Korea | ₩23.72 Billion |
|
DC HEALTHCARE HOLDINGS BERHAD
KLSE:0283
|
Malaysia | RM71.79 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Indivior PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see INDV current and non-current assets.
Liquidity & Leverage Metrics
Indivior PLC Total Liabilities Ratios Explained
Indivior PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -6.63 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Indivior PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Indivior PLC (2011–2024)
The table below shows the annual total liabilities of Indivior PLC from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX1.67 Billion ≈ $202.83K |
-15.17% |
| 2023-12-31 | GBX1.97 Billion ≈ $239.08K |
+14.38% |
| 2022-12-31 | GBX1.72 Billion ≈ $209.03K |
+5.46% |
| 2021-12-31 | GBX1.63 Billion ≈ $198.20K |
+12.42% |
| 2020-12-31 | GBX1.45 Billion ≈ $176.30K |
+0.42% |
| 2019-12-31 | GBX1.44 Billion ≈ $175.57K |
-2.57% |
| 2018-12-31 | GBX1.48 Billion ≈ $180.19K |
-10.08% |
| 2017-12-31 | GBX1.65 Billion ≈ $200.39K |
+9.51% |
| 2016-12-31 | GBX1.50 Billion ≈ $182.99K |
+23.68% |
| 2015-12-31 | GBX1.22 Billion ≈ $147.95K |
-0.49% |
| 2014-12-31 | GBX1.22 Billion ≈ $148.68K |
+148.37% |
| 2013-12-31 | GBX492.00 Million ≈ $59.86K |
+19.42% |
| 2012-12-31 | GBX412.00 Million ≈ $50.13K |
+35.08% |
| 2011-12-31 | GBX305.00 Million ≈ $37.11K |
-- |
About Indivior PLC
Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly … Read more